OR WAIT null SECS
February 01, 2024
With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.
The final guidance provides specific recommendations for CMC, pharmacology, toxicology, and clinical study design for CAR-T cell products.
An interview with Steffen Thirstrup, chief medical officer, European Medicines Agency (EMA).
January 31, 2024
The immune-resetting peptide, developed by Revolo Biotherapeutics, received positive results from its Phase IIb study.
The final guidance provides recommendations for developing gene therapy products incorporating genome editing of human somatic cells.
January 30, 2024
IMU Biosciences has secured £11.5 million in its Series A financing round.
January 29, 2024
The company issued the recall because of a package mislabeling problem.
The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.
January 26, 2024
Getinge has announced the inauguration of its new Global Centre of Excellence for Chemistry in the United Kingdom
The annual industry report of the Pharmapack Europe event suggests there will be significant innovation in inhaled pulmonary and intranasal drug delivery in 2024.